BBIO vs KARD: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
BBIO is the larger of the two ($15.69B market cap): the incumbent the market prices for continued execution (140.83x forward earnings, beta 0.95). KARD is the smaller challenger ($1.86B), priced similarly on forward earnings (-6.91x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
BBIO vs KARD: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BBIO | KARD | What it tells you |
|---|---|---|---|
| Market cap | $15.69B | $1.86B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 140.83 | -6.91 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Price vs 52-week range | 74% of range | 43% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how BBIO and KARD affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BBIO and KARD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BBIO and KARD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does BridgeBio Pharma (BBIO) do?
BridgeBio Pharma (NASDAQ: BBIO) is a Palo Alto-based biopharmaceutical company focused on genetic diseases and genetically driven cancers. Its commercial engine is Attruby (acoramidis), an oral TTR stabilizer approved by the FDA in November 2024 for transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive and often underdiagnosed heart condition. Attruby competes in a market long dominated by Pfizer's tafamidis franchise, and BridgeBio has been rapidly building prescriber and patient uptake since launch.
What does Kardigan (KARD) do?
Kardigan, Inc. (Nasdaq: KARD) is a clinical-stage precision cardiovascular therapeutics company based in Princeton, New Jersey, founded in 2023 and formerly known as EnCarda. It was created by former executives of MyoKardia, the team behind mavacamten (Camzyos), the hypertrophic cardiomyopathy drug that led to Bristol Myers Squibb's roughly $13 billion acquisition of MyoKardia. Kardigan is developing three late-stage candidates that target the underlying biology of specific heart conditions where treatments are limited: danicamtiv (a cardiac myosin activator in-licensed from BMS) for genetic dilated cardiomyopathy, ataciguat for calcific aortic valve stenosis, and tonlamarsen for acute severe hypertension. It pairs these programs with the Prolaio AI and real-world-data platform, branded as Cardiac Intelligence, to sharpen trial design.
BBIO vs KARD: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- BBIO drivers: Attruby (acoramidis) commercial ramp; Pipeline diversification and 2026 filings.
- KARD drivers: Late-stage cardiovascular pipeline; MyoKardia pedigree and BMS-sourced asset.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is concentration: Attruby is BridgeBio's only approved commercial product, so near-term performance is highly dependent on a single therapy in a competitive market. For KARD, kardigan is pre-revenue and deeply loss-making, so its value depends on clinical trial outcomes that remain years away and could fail.
BBIO or KARD: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BBIO if you believe its drivers more; KARD if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BBIO and KARD guides.
BBIO vs KARD: the full fundamentals
BBIO. BBIO trades at a rich multiple of trailing revenue, reflecting expectations for continued Attruby growth and pipeline launches rather than current profits. Revenue is expanding rapidly, but the company still posts large net losses as it invests in commercialization and R&D. A $500 million buyback authorized in May 2026 and a cash position near $940 million give it near-term financial flexibility.
KARD. Kardigan generates no product revenue and funds a large research budget, producing net losses near $56 million in Q1 2026 and roughly $192 million for full-year 2025. Its valuation reflects pipeline potential, not current financials, and the roughly $2 billion market cap sits against zero sales. The IPO and prior cash give a runway management expects to last into 2028.
Headline figures (approximate, Q1 2026): BBIO shows revenue (q1 2026) ~$195M, attruby net revenue (q1 2026) ~$181M, revenue (ttm) ~$500M-$580M, net income (ttm) ~-$733M; KARD shows revenue (ttm) ~$0 (pre-commercial), net loss (ttm) ~-$230M, net loss (q1 2026) ~-$56M, cash & investments (pre-ipo) ~$287M.
The bottom line: BBIO vs KARD
BBIO and KARD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BBIO and KARD exposure against your real portfolio. It is not an investment adviser.
Wondering how BBIO or KARD fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in BridgeBio Pharma with AI
Connect the broker you already use and ask Walnut's AI how BBIO fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between BBIO and KARD?
+
BridgeBio Pharma (NASDAQ: BBIO) is a Palo Alto-based biopharmaceutical company focused on genetic diseases and genetically driven cancers. Kardigan, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BBIO or KARD the better stock?
+
Neither is universally better. BBIO is the larger incumbent; KARD is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BBIO or KARD?
+
On forward P/E (as of August 2026), BBIO trades at 140.83x and KARD at -6.91x, so KARD is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BBIO and KARD?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BBIO vs KARD?
+
BBIO: The dominant risk is concentration: Attruby is BridgeBio's only approved commercial product, so near-term performance is highly dependent on a single therapy in a competitive market. Pfizer's entrenched tafamidis franchise and Alnylam's vutrisiran (Amvuttra) are well-funded rivals fighting for the same patients. Any FDA delay, rejection, request for more data, or narrower-than-expected label for BBP-418, encaleret, or infigratinib would push out the diversification timeline. The company is still deeply unprofitable, with large trailing net losses and ongoing cash burn on R&D and commercialization. Pricing pressure, slower diagnosis growth, or a valuation that already embeds heavy optimism could all weigh on the shares. KARD: Kardigan is pre-revenue and deeply loss-making, so its value depends on clinical trial outcomes that remain years away and could fail. Its S-1 disclosures included going-concern language tied to pre-IPO cash, and while the IPO extended the runway into 2028, the company will likely need to raise more capital and could dilute shareholders. Any negative or delayed data from danicamtiv, ataciguat, or tonlamarsen could sharply reduce the stock, and a post-IPO lock-up expiration may add selling pressure. As a brand-new listing with a roughly $2 billion valuation against no earnings, the shares can be highly volatile. It also competes with larger, better-capitalized cardiovascular players.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BBIO or KARD; figures are approximate and dated (as of August 2026). Verify current data before investing.